logo
logo

Eli Lilly acquires Morphic Holding for $3.2B, focusing on IBD treatment opportunities

Jul 08, 2024•about 1 year ago

Acquiring Company

Eli Lilly and Company

Acquired Company

Morphic Therapeutic

IndianapolisWalthamPharmaceuticalManufacturingHealth CareBiopharmaTherapeuticsBiotechnology

Description

Eli Lilly has purchased Morphic Holding for $3.2 billion, intending to leverage its expertise in the field of gastroenterology. The acquisition is in line with Lilly's commitment to developing new therapies for the benefit of patients, especially in the treatment of inflammatory bowel disease (IBD).

Company Information

Company

Eli Lilly and Company

Location

Indianapolis, Indiana, United States

About

Lilly is a medicine company turning science into healing to make life better for people around the world. They have been pioneering life-changing discoveries for nearly 150 years, and today their medicines help more than 51 million people across the globe. Lilly is focused on redefining diabetes care, treating obesity, advancing the fight against Alzheimer's disease, providing solutions to immune system disorders, and transforming difficult-to-treat cancers into manageable diseases.

DealWatch™ Score

71
High M&A Activity

M&A Opportunity Analysis

Get personalized insights on M&A opportunities

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Related People

Lucas hidden

hidden
hidden

Gordon hidden

hidden
hidden

Melissa hidden

hidden
hidden